Endoscopic Ultrasound-Guided Pancreatic Transmural Stenting and Transmural Intervention

by Takeshi Ogura, Hideko Ohama, Kazuhide Higuchi
Published 2020-07-01

Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases

by Akira Asai, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Shinya Fukunishi, Kazuhide Higuchi
Published 2021-06-01

Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC

by Akira Asai, Yusuke Tsuchimoto, Hideko Ohama, Shinya Fukunishi, Yasuhiro Tsuda, Makiko Kobayashi, Kazuhide Higuchi, Fujio Suzuki
Published 2017-04-01

Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery

by Shuichiro Shiina, Koki Sato, Ryosuke Tateishi, Motonori Shimizu, Hideko Ohama, Takeshi Hatanaka, Masashi Takawa, Hiroaki Nagamatsu, Yasuharu Imai
Published 2018-01-01

Efficacy and safety of laparoscopic hepatectomy for hepatocellular carcinoma comorbid with cirrhosis

by Yoshihiro Inoue, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Tetsuji Terazawa, Akira Asai, Shinya Fukunishi, Junji Okuda, Kazuhide Higuchi, Kazuhisa Uchiyama
Published 2020-09-01

Comparison of SARC-F Score among Gastrointestinal Diseases

by Kosuke Ushiro, Hiroki Nishikawa, Masahiro Matsui, Takeshi Ogura, Toshihisa Takeuchi, Masahiro Goto, Shiro Nakamura, Kazuki Kakimoto, Takako Miyazaki, Shinya Fukunishi, Akira Asai, Hideko Ohama, Keisuke Yokohama, Hidetaka Yasuoka, Kazuhide Higuchi
Published 2021-09-01

Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients

by Abeer Hassan, Yasuhiro Tsuda, Akira Asai, Keisuke Yokohama, Ken Nakamura, Tetsuya Sujishi, Hideko Ohama, Yusuke Tsuchimoto, Shinya Fukunishi, Usama M. Abdelaal, Usama A. Arafa, Ali T. Hassan, Ali M. Kassem, Kazuhide Higuchi
Published 2015-01-01

What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Kazuya Kariyama, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo
Published 2021-02-01

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

by Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Published 2021-07-01

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Published 2021-08-01